FOR IMMEDIATE RELEASE

Press Contact:
Cerexa‚ Inc.
Stan Abel
Phone: 510–747–3911
seabel@cerexa.com

Press Contact:
Noonan Russo
Jane Petrino
Phone: 212–845–4274
jane.patrino@eurorscg.com

Cerexa to Present at Future Leaders Conference

ALAMEDA‚ Calif.‚ March 28‚ 2006 –– Cerexa‚ Inc. (www.cerexa.com) today announced that Dennis G. Podlesak‚ Chief Executive Officer, will present at the Future Leaders in the Biotech Industry conference on Thursday‚ March 30‚ 2006 at 9:00 a.m. at the Millennium Broadway Hotel in New York City. Mr. Podlesak will provide a brief corporate overview and discuss the company’s lead product candidate‚ Ceftaroline (formerly PPI-0903).

About Cerexa

Cerexa‚ Inc.‚ located in Alameda‚ California‚ is an innovation driven‚ biopharmaceutical company committed to developing and commercializing a growing portfolio of novel anti–infective therapies for the treatment of serious and life–threatening infections. Cerexa’s lead compound‚ ceftaroline acetate‚ is a next–generation cephalosporin that is currently being investigated as a potential treatment for cSSSI. Cerexa licensed from Takeda Pharmaceutical Company Limited the exclusive right to develop and commercialize ceftaroline. For additional company information‚ please visit www.cerexa.com.

###